Table 3 

Drugs with significant enrichment to diurnal signature in the Connectivity Map 

rank 
drug 
mean 
n 
pvalue 


1 
sirolimus 
0.68 
10 
0 
2 
LY294002 
0.54 
17 
0 
3 
wortmannin 
0.62 
8 
0.0001 
4 
trichostatin A 
0.48 
12 
0.0012 
5 
resveratrol 
0.61 
5 
0.0026 
6 
5182598 
0.78 
2 
0.0043 
7 
estradiol 
0.39 
10 
0.0079 
8 
iloprost 
0.71 
3 
0.0105 
9 
tacrolimus 
0.56 
3 
0.0153 
10 
arachidonyltrifluoromethane 
0.75 
2 
0.02 
11 
deferoxamine 
0.49 
3 
0.0292 
12 
fludrocortisone 
0.60 
2 
0.0429 
13 
quercetin 
0.53 
2 
0.0607 
14 
TTNPB 
0.57 
2 
0.0645 
15 
vorinostat 
0.53 
2 
0.0734 
16 
fulvestrant 
0.39 
7 
0.0858 
17 
raloxifene 
0.15 
3 
0.0876 
18 
rottlerin 
0.43 
3 
0.0945 


The drugs with significant connectivity to the diurnal signature are ranked in the order of significance of the connectivity score as judged by the permutation pvalue (column labeled "pvalue"). Significance cutoff was set at pvalue = 0.1. The permutation pvalue estimates the likelihood that the enrichment of a given set of postdose gene expression changes (instances) by a given drug, relative to all available postdose changes in the CMAP database (for all drugs) would be observed by random chance. Mean: the arithmetic mean of the connectivity scores for the postdose changes by the given drug; N: the number of instances of a given drug in CMAP database[23]. 

Loboda et al. BMC Medical Genomics 2009 2:7 doi:10.1186/1755879427 